TREND: M&A activity heats up in the pharma sector as big payers increase focus on orphan drugs

10 August 2015

Rare disease market has renewed interest from the pharma companies as is visible in the heated merger and acquisition activity in the sector.

Ireland-headquartered drugmaker Shire’s (LSE: SHP) latest takeover bid for Baxalta (NYSE: BXLT), a company with a drug portfolio for rare or orphan diseases in hematology, oncology and immunology, is yet another confirmation big pharma is drawn to the segment.

The pharma sector over the past few months has been witness to hectic merger and acquisition activity. There have been more than a few large deals between May and July alone this year. In addition to the number of bids, the amount offered for the takeover has been staggering, indicating the rush to snap up the potential growth drivers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK